Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)
一项随机 II 期辅助治疗试验比较了两种不同疗程的埃克替尼治疗 II-IIIA 期 EGFR 阳性肺腺癌患者(ICOMPARE 研究)的疗效。
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2023.101565
Lv, C; Wang, R; Li, S; Yan, S; Wang, Y; Chen, J; Wang, L; Liu, Y; Guo, Z; Wang, J; Pei, Y; Yu, L; Wu, N; Lu, F; Gao, F; Chen, J; Liu, Y; Wang, X; Li, S; Han, B; Zhang, L; Ma, Y; Ding, L; Wang, Y; Yuan, X; Yang, Y